Decision Resources, Inc., June 2006, Pages: 28
the Use of Pharmacogenomics in Drug Development
United States
Americans’ Attitudes Toward Pharmacogenomics and Personalized Medicine
Europe
Japan
- Outlook
The Public’s Perspective
Pricing
Decision Resources, Inc., March 2011, Pages: 22
?
- Pharmacogenomic biomarker data are only voluntarily submitted to the FDA in drug applications, but there is an unspoken consensus that biomarker data are preferred because they facilitate the assessment of drug
Global Industry Analysts, Inc., Oct 2010, Pages: 659
Diseases Testing 4
Pharmacogenomics 4
Cancer Screening 4
2. INDUSTRY OVERVIEW 5
Global Market Outlook 5
Molecular Diagnostics - The Fastest Growing Medical
Diagnostic Technology 5
Current and Future
Decision Resources, Inc., Nov 2006, Pages: 31
of the arrival and impact of pharmacogenomic blockbusters.
Outlook: a discussion of the dangers of under-forecasting and the need to improve forecasting going forward in order to more readily identify potential
Arrowhead Publishers, May 2010, Pages: 261
.
Key features of Arrowhead’s Personalized Medicine 2010 include:
- Case studies of leading pharmacogenomic products
- Analysis of the personalized medicine market, including seven major market sales
RNCOS E-Services Private Limited, March 2011, Pages: 70
Global Bioinformatics Market Outlook Major countries of the world have always tried to build strategies that ensure better development of strong biotechnology sector and in this aim; bio-informatics
Decision Resources, Inc., Dec 2007, Pages: 31
of pharmacogenomics may cause AD patients to be turned away from certain therapies—but may also lead to better dosing and reduce the possibility of side effects and adverse drug interactions. Regardless: the soaring
Decision Resources, Inc., Aug 2006, Pages: 31
Issues
Reimbursement, Ethical, and Legal Issues
Spectrum Expert Commentary: FDA Establishes New Processes:
Pharmacogenomic Data Submissions and a Drug-Test Codevelopment Pathway
Outlook
Tables:
1
Business Insights, April 2008, Pages: 265
on pharmacogenomic data submission
Drug-diagnostic co-development concept paper
Draft guidance on multivariate analysis
In vivo biomarker diagnostics
Chapter 2 Biomarker discovery and validation
Summary
Decision Resources, Inc., Nov 2009, Pages: 28
pharmacogenomic markers than the United States or Japan. For how many drugs does the EMEA support pharmacogenomic testing? What is Japan’s position on pharmacogenomic testing and on reviewing these data?
Scope
RNCOS E-Services Private Limited, March 2012, Pages: 85
Bioinformatics Market Outlook to 2015 During the past decade, the bioinformatics market has significantly evolved across the globe on back of rising genomics industry. The increasing application
TriMark Publications, Feb 2012, Pages: 214
to generate interest with the move of healthcare towards pharmacogenomics.
This TriMark Publications report examines the use of companion diagnostics in personalized medicine and cancer therapy. The study
Decision Resources, Inc., March 2007, Pages: 28
into three phases: infectious diseases; blood screening; and pharmacogenomic testing, genetic testing, predictive testing, and companion diagnostics.
Why does scope for greater innovation and greater sales
Business Insights, Oct 2009, Pages: 141
Innovations in Oncology Diagnostics: Technological Advances, Growth Opportunities and Future Market Outlook Despite public policy measures to prevent cancer, such as tobacco control and vaccination
Renub Research, Feb 2011, Pages: 60
, Biochips, Pharmacogenomics, SNP Genotyping, Pharmacogenetics, Point of Care Testing, Genetic Screening and Pharmacoproteomics markets data from (2007 to 2014) has been provided in the report.
Report reviews
Venture Planning Group, Jan 2012, Pages: 85
Relationship
d. Industry-University Ventures
e. Technological Environment
f. Decentralization
g. Health Care Expenditures
h. Physician Population
i. Hospital Indicators
4. Outlook for the In Vitro Diagnostics
Decision Resources, Inc., Nov 2008, Pages: 26
. What are the steps in this process? What is the time frame for commercialization?
Scope:
-NGS in context: data and trends that pose current challenges to R&D; pharmacogenomics; benefits of NGS
Takeda Pacific, Feb 2010, Pages: 144
drug R&D spending, trends, major diseases, applications, M&As, alliances, tools & technologies, products and R&D services. This report provides a detailed outlook of the market for biomarkers and related
Decision Resources, Inc., March 2008, Pages: 42
How to Get Ahead with Pharmacogenomics Introduction
Pharmacogenomics (PGx) is an evolutionary—not a revolutionary—process. The “blockbuster” business model is, of course, still relevant
